Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs.
The introduction of 5-HT3 antagonists, such as ondansetron, as antiemetic agents has transformed the management of patients receiving chemotherapy or radiation therapy. Studies in animal models with NK1 antagonists suggest that these represent a new class of antiemetic agents having a broader spectrum of activity than 5-HT3 antagonists. Compounds of this class may prove to be more effective in man against delayed emesis induced by cisplatin, post-operative nausea and vomiting and motion sickness. Thus, they have the potential to complement 5-HT3 antagonists and so provide a further advance in the management of nausea and vomiting.
Bountra
C
C
Division of Biology, Glaxo Research and Development Ltd., Ware, Herts., UK.
Gale
J D
JD
Gardner
C J
CJ
Jordan
C C
CC
Kilpatrick
G J
GJ
Twissell
D J
DJ
Ward
P
P
D000818:Animals; D000932:Antiemetics / Q000494:pharmacology / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D064729:Neurokinin-1 Receptor Antagonists; D012018:Reflex / Q000502:physiology; D014839:Vomiting / Q000209:etiology* / Q000503:physiopathology* / Q000517:prevention & control
D000932:Antiemetics; D064729:Neurokinin-1 Receptor Antagonists